{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:08Z","timestamp":1750538408743,"version":"3.41.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 59-year-old man with a parapharyngeal paraganglioma incidentally discovered on a cervical swelling was referred to our nuclear medicine department for a morpho-metabolic assessment. An <jats:sup>18<\/jats:sup>F-FDG PET\/CT was initially performed and found an intense hypermetabolism of the lesion and a hypermetabolism of the periadrenal brown fat evoking catecholamine secretion. An additional <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT was performed, showing an overexpression of the somatostatin receptors of this isolated paraganglioma. After multidisciplinary discussion, a peptide receptor radionuclide therapy with somatostatin analogs using <jats:sup>177<\/jats:sup>Lu-DOTATATE as a compassionate measure was carried out.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003753","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T21:07:26Z","timestamp":1623445646000},"page":"e71-e73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma"],"prefix":"10.1097","volume":"47","author":[{"given":"Agathe","family":"Deville","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliia","family":"Pinigina","sequence":"additional","affiliation":[{"name":"Service d\u2019Endocrinologie Diab\u00e9tologie et Nutrition, H\u00f4pital Cardiologique, Hospices Civils de Lyon, Bron"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Al Mansour","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Abeillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremie","family":"Tordo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-15-1073","article-title":"Moving beyond \u201clumpology\u201d: PET\/CT imaging of pheochromocytoma and paraganglioma","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-019-01895-z","article-title":"Novel PET tracers: added value for endocrine disorders","volume":"64","year":"2019","journal-title":"Endocrine"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1210\/jc.2019-00018","article-title":"The role of 68Ga-DOTA-octreotate PET\/CT in follow-up of SDH-associated pheochromocytoma and paraganglioma","volume":"104","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CCO.0000000000000589","article-title":"Malignant pheochromocytoma and paraganglioma: management options","volume":"32","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41440-020-0531-0","article-title":"Recent advances in the management of pheochromocytoma and paraganglioma","volume":"43","year":"2020","journal-title":"Hypertens Res"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","year":"2016","journal-title":"Med Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with 90Y\/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:43Z","timestamp":1750536403000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003753","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,6,11]]}}}